LEXX Lexaria Bioscience Corp. Stock Quote

LEXX [NASD]

Consumer Defensive | Packaged Foods | Canada

Index	-	P/E	-	EPS (ttm)	-0.87	Insider Own	5.90%	Shs Outstand	5.10M	Perf Week	-6.53%
Market Cap	33.08M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	0.00%	Shs Float	4.25M	Perf Month	-4.26%
Income	-3.50M	PEG	-	EPS next Q	-	Inst Own	8.20%	Short Float	8.80%	Perf Quarter	-5.97%
Sales	0.80M	P/S	41.34	EPS this Y	10.30%	Inst Trans	-	Short Ratio	1.88	Perf Half Y	23.05%
Book/sh	2.03	P/B	3.10	EPS next Y	-	ROA	-51.40%	Target Price	12.76	Perf Year	16.67%
Cash/sh	1.62	P/C	3.89	EPS next 5Y	-	ROE	-53.80%	52W Range	3.98 - 12.50	Perf YTD	-15.76%
Dividend	-	P/FCF	-	EPS past 5Y	-0.60%	ROI	-163.40%	52W High	-49.68%	Beta	1.93
Dividend %	-	Quick Ratio	43.50	Sales past 5Y	92.10%	Gross Margin	79.60%	52W Low	58.24%	ATR	0.28
Employees	4	Current Ratio	43.80	Sales Q/Q	411.30%	Oper. Margin	-	RSI (14)	41.89	Volatility	4.15% 4.38%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-0.50%	Profit Margin	-	Rel Volume	0.29	Prev Close	6.30
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	198.41K	Price	6.29
Recom	2.00	SMA20	-4.32%	SMA50	-1.74%	SMA200	2.52%	Volume	15,600	Change	-0.16%

Oct-22-21 12:52PM	New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.'s Technology as an Alternative to Smoking and Vaping Benzinga
Oct-20-21 11:19AM	Lexaria Bioscience Corp.'s DehydraTECH(TM) Impacting the Pharmaceutical Industry Benzinga
08:30AM	Lexaria THC Test Results Come in as MORE Act Gains Momentum in Congress Newsfile
Oct-13-21 11:00AM	Lexaria's Technology Proven to Deliver Oral THC More Effectively News Direct
Oct-12-21 08:17AM	IBN (InvestorBrandNetwork) Announces Latest Episode of Stock2Me Podcast Featuring Lexaria Bioscience Corp. Chairman & CEO Chris Bunka GlobeNewswire
Oct-11-21 05:21AM	LEXX: Lexarias DehydraTECH Shows Fast Delivery Zacks Small Cap Research
Oct-06-21 12:07PM	Lexaria Bioscience Corp. Oral Drug Use Technology Nets Zacks Research Coverage Benzinga
Oct-05-21 10:48AM	DehydraTECH(TM) Nicotine Pouches Could Make Smoking Obsolete Newsfile
09:05AM	Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results News Direct
Sep-30-21 12:27PM	Lexaria Bioscience Corp.'s Versatile DehydraTECH(TM) Technology Improving Taste, Bioabsorption, Efficacy of Drugs Benzinga
Sep-24-21 12:08PM	Lexaria Bioscience Corp.'s Solution For Faster And More Effective Drug Delivery Benzinga
Sep-23-21 09:44AM	LEXX: An Investment Thats Easy to Swallow Zacks Small Cap Research
06:00AM	BTV Highlights Promising Investment Opportunities Newsfile
Sep-14-21 08:30AM	Lexaria Takes Another Step Towards NDA Filing for DehydraTECH- CBD Newsfile
Sep-09-21 07:05AM	Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference ACCESSWIRE
Sep-08-21 07:05AM	Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension ACCESSWIRE -5.84%
Sep-07-21 07:58PM	BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs Newsfile +11.43%
07:05AM	Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period ACCESSWIRE
Aug-17-21 08:30AM	Winning Formulation; Lexaria Takes Strategic Aim at High Value Hypertension and Antiviral Therapeutics Markets with Robust Drug Delivery Technology Newsfile
Jul-29-21 07:05AM	Lexaria's DehydraTECH-CBD Lowers Blood Pressure ACCESSWIRE
Jul-28-21 07:05AM	DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores ACCESSWIRE
Jul-27-21 07:15AM	Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2 ACCESSWIRE
Jul-26-21 02:40PM	Lexaria Receives US$3,817,643 From Warrant Exercises ACCESSWIRE
Jul-22-21 07:05AM	Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy ACCESSWIRE -12.44%
Jul-21-21 07:05AM	Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3 ACCESSWIRE +28.07%
Jul-15-21 07:05AM	Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council ACCESSWIRE
Jul-13-21 07:05AM	Lexaria Receives Patent Protection in Japan ACCESSWIRE
Jul-05-21 08:00AM	Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets ACCESSWIRE
Jun-29-21 04:05PM	Lexaria Announces 2021 Annual Meeting Results ACCESSWIRE
Jun-28-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing GlobeNewswire
Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 GlobeNewswire
Jun-17-21 08:30AM	Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM) Newsfile +5.04%
Jun-15-21 07:05AM	Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs ACCESSWIRE
Jun-09-21 07:00AM	Lexaria Provides Progress Report on Six R&D Programs ACCESSWIRE
Jun-07-21 07:00AM	Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 ACCESSWIRE
Jun-03-21 07:00AM	Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus ACCESSWIRE +8.17%
May-25-21 10:39AM	Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study Newsfile
May-20-21 07:05AM	Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever ACCESSWIRE
May-12-21 07:05AM	Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted ACCESSWIRE
May-07-21 09:03AM	Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast Newsfile
09:00AM	Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET ACCESSWIRE
May-06-21 07:00AM	Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 ACCESSWIRE +22.07%
06:00AM	BTV Explores Investment Options in Life Sciences Newsfile
Apr-27-21 02:28PM	Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video Newsfile
Apr-22-21 07:00AM	Lexaria Commences Human Clinical Hypertension Study ACCESSWIRE +11.34%
Apr-20-21 05:24AM	We're Hopeful That Lexaria Bioscience (NASDAQ:LEXX) Will Use Its Cash Wisely Simply Wall St.
Apr-15-21 04:05PM	Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants ACCESSWIRE
08:58AM	Lexaria Bioscience: Turning the Tide on Hypertension Newsfile
Apr-14-21 07:00AM	Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network ACCESSWIRE
Apr-08-21 08:30AM	Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace Newsfile
Apr-06-21 07:05AM	Lexaria to Evaluate DehydraTECH(TM) in Multiple New Markets ACCESSWIRE
Mar-24-21 07:00AM	Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages ACCESSWIRE
Mar-23-21 07:00AM	Lexaria to Present at the Benzinga Biotech Small Cap Conference on March 24, 2021 at 9:45 AM ET ACCESSWIRE
Mar-16-21 07:00AM	Lexaria's Antiviral Drug Evaluation Program Progressing ACCESSWIRE +5.85%
Mar-15-21 07:00AM	Rapid Progress in Hypertension Studies by Lexaria ACCESSWIRE
Mar-11-21 07:10AM	Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021 ACCESSWIRE
Mar-09-21 08:30AM	Could DehydraTECH(TM) CBD be Worth $3 Billion a Year to Lexaria? Newsfile
Feb-16-21 06:00AM	Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection CNW Group
Feb-11-21 07:15AM	Lexaria Expands R&D Program to Address US$28 Billion Hypertension Market with Addition of Two Human Clinical Studies ACCESSWIRE
Feb-09-21 08:30AM	Lexaria Outlook is Promising After Jazz Acquisition of GW Newsfile +12.63%
Feb-01-21 06:30AM	Lexaria Provides Guidance on Upcoming R&D ACCESSWIRE
Jan-28-21 10:09AM	Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast Newsfile
Jan-15-21 03:35PM	Lexaria Appoints New Board Member ACCESSWIRE
06:30AM	Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants ACCESSWIRE

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience